tetano
Editor, Senior Moderator
Eur Respir J
. 2020 Nov 5;2003142.
doi: 10.1183/13993003.03142-2020. Online ahead of print.
The Impact of COVID-19 on Patients with Asthma
Jos? Luis Izquierdo[SUP] 1 2 [/SUP], Carlos Almonacid[SUP] 2 3 [/SUP], Yolanda Gonz?lez[SUP] 4 [/SUP], Carlos Del Rio-Berm?dez[SUP] 4 [/SUP], Julio Ancochea[SUP] 5 6 7 [/SUP], Remedios C?rdenas[SUP] 8 [/SUP], Joan B Soriano[SUP] 5 6 7 [/SUP]
Affiliations
Abstract
Background: An association between the severity of COVID-19 and the presence of certain chronic conditions has been suggested. However, unlike influenza and other viruses, the disease burden in patients with asthma has been less evident.
Objective: To understand the impact of COVID-19 in patients with asthma.
Methods: Using big data analytics and artificial intelligence through the SAVANA Manager? clinical platform, we analysed clinical data from patients with asthma from January 1st to May 10th, 2020.
Results: Out of 71 182 patients with asthma, 1006 (1.41%) suffered from COVID-19. Compared to asthmatic individuals without COVID-19, patients with asthma and COVID-19 were significantly older (55 versus 42 years), predominantly female (66% versus 59%), smoked more frequently, and had higher prevalence of hypertension, dyslipidemias, diabetes, and obesity. Allergy-related factors such as rhinitis and eczema were less common in asthmatic patients with COVID-19 (p<.001). Higher prevalence of these comorbidities was also observed in patients with COVID-19 who required hospital admission. The use of inhaled corticosteroids (ICS) was lower in patients who required hospitalisation due to COVID-19, as compared to non-hospitalised patients (48.3% versus 61.5%; OR: 0.58: 95% CI 0.44-0.77). Although patients treated with biologics (n=865; 1.21%) showed increased severity and more comorbidities at the ENT level, COVID-19-related hospitalisations in these patients were relatively low (0.23%).
Conclusion: Patients with asthma and COVID-19 were older and at increased risk due to comorbidity-related factors. ICS and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection.
. 2020 Nov 5;2003142.
doi: 10.1183/13993003.03142-2020. Online ahead of print.
The Impact of COVID-19 on Patients with Asthma
Jos? Luis Izquierdo[SUP] 1 2 [/SUP], Carlos Almonacid[SUP] 2 3 [/SUP], Yolanda Gonz?lez[SUP] 4 [/SUP], Carlos Del Rio-Berm?dez[SUP] 4 [/SUP], Julio Ancochea[SUP] 5 6 7 [/SUP], Remedios C?rdenas[SUP] 8 [/SUP], Joan B Soriano[SUP] 5 6 7 [/SUP]
Affiliations
- PMID: 33154029
- DOI: 10.1183/13993003.03142-2020
Abstract
Background: An association between the severity of COVID-19 and the presence of certain chronic conditions has been suggested. However, unlike influenza and other viruses, the disease burden in patients with asthma has been less evident.
Objective: To understand the impact of COVID-19 in patients with asthma.
Methods: Using big data analytics and artificial intelligence through the SAVANA Manager? clinical platform, we analysed clinical data from patients with asthma from January 1st to May 10th, 2020.
Results: Out of 71 182 patients with asthma, 1006 (1.41%) suffered from COVID-19. Compared to asthmatic individuals without COVID-19, patients with asthma and COVID-19 were significantly older (55 versus 42 years), predominantly female (66% versus 59%), smoked more frequently, and had higher prevalence of hypertension, dyslipidemias, diabetes, and obesity. Allergy-related factors such as rhinitis and eczema were less common in asthmatic patients with COVID-19 (p<.001). Higher prevalence of these comorbidities was also observed in patients with COVID-19 who required hospital admission. The use of inhaled corticosteroids (ICS) was lower in patients who required hospitalisation due to COVID-19, as compared to non-hospitalised patients (48.3% versus 61.5%; OR: 0.58: 95% CI 0.44-0.77). Although patients treated with biologics (n=865; 1.21%) showed increased severity and more comorbidities at the ENT level, COVID-19-related hospitalisations in these patients were relatively low (0.23%).
Conclusion: Patients with asthma and COVID-19 were older and at increased risk due to comorbidity-related factors. ICS and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection.